A Study of VET3-TGI in Patients With Solid Tumors

NCT06444815 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
Microsatellite Stable Colorectal Cancer
Head and Neck Squamous Cell Carcinoma
Cervical Cancer
Kidney Cancer
Renal Cell Carcinoma
Melanoma Stage IV
Merkel Cell Carcinoma of Skin
Mesothelioma
Non-small Cell Lung Cancer
Cutaneous Squamous Cell Carcinoma (CSCC)
Urothelial Carcinoma Bladder
Squamous Cell Carcinoma

Interventions

DRUG: VET3-TGI
DRUG: Atezolizumab

Sponsor

KaliVir Immunotherapeutics